Background: Propofol is used to induce deep sedation or general anaesthesia for procedures in children. Adjuvants, such as ketamine, are routinely added to reduce the dose of propofol required and propofol-related adverse events. We conducted a randomised controlled trial to determine the effective bolus dose of propofol in combination with ketamine that induces adequate depth of anaesthesia in 50% of children (ED 50 ) undergoing gastro-duodenoscopy. Methods: Children were randomised to one of four doses of ketamine: 0 (control), 0.25, 0.5, and 1 mg kg
Paediatric patients often require deep sedation, general anaesthesia, or both to tolerate medical procedures, such as lumbar puncture, fracture reduction, and upper gastrointestinal tract endoscopy. Various drugs, such as propofol, opioids, benzodiazepines, and ketamine, either alone or in combination, have been used. 1e5 Despite widespread use and expertise, there is no consensus for a standardised drug regimen in such scenarios. Ketamine offers numerous advantages as an adjuvant, including maintenance of airway tone, reduced apnoea risk compared with opioids, and haemodynamic stability. However, the side effects of ketamine, such as nausea and psychotomimetic effects in children, limit the dose that can be safely administered. Recent systematic reviews and meta-analyses have shown that the use of propofol combined with an adjuvant, such as ketamine or an opioid (fentanyl), for procedural sedation/ anaesthesia is more efficacious and safe compared with either an opioid/benzodiazepine combination or propofol alone. 1,6e13 A recent meta-analysis of ketamine plus propofol for procedural sedation and analgesia in the emergency department in adults found that the risk of hypotension, bradycardia, and respiratory complications requiring intervention significantly decreased with the combination of ketamine and propofol compared with propofol alone. 13 The authors did not recommend a dose ratio for propofol and ketamine, and noted that the 'optimal ketamine-propofol proportion has not been determined' in adults or children.
To address this gap, we conducted a double-blind randomised controlled trial. Our primary objective was to determine the median effective bolus dose (mg kg
À1
) of propofol in combination with ketamine in the following doses: 0, 0.25, 0.5, and 1 mg kg
, which produces an adequate depth of anaesthesia to prevent excessive movement, gagging, or coughing on endoscope insertion in children (ED 50 ). A secondary objective was to explore the type and frequency of adverse events associated with the propofoleketamine dose combinations.
Methods

Design
We conducted a single-centre, double-blind, randomised fourarm trial to evaluate a range of dose combinations of propofol and ketamine administered to produce deep sedation/anaesthesia to children aged 3e12 yr undergoing elective gastroduodenoscopy. The Research Ethics Board at The Hospital for Sick Children (University of Toronto, ON, Canada) approved the trial. Regulatory approval was obtained from Health Canada for the use of ketamine. The study was registered with www.clinicaltrials.gov (December 2013, NCT 02295553).
Exclusion criteria were weight <10 kg; significant gastroesophageal reflux, vomiting, or both; known gastrointestinal bleeding; obesity (BMI >35 kg m À2 ); oral sedation (premedication) before i.v. placement; and any contraindication to study medications. We obtained informed written consent from parents, and informed assent from all children aged 7e12 yr.
Randomisation and masking
Eligible children were allocated sequentially using a doubleblind, randomisation system in a 1:1:1:1 ratio, using randomnumber generating computer software and a random number block 4 design to receive one of four doses of ketamine: 0 (control group), 0.25, 0.5, or 1 mg kg À1 (Ketamine 50 mg ml
À1
HCl injection USP; Sandoz, Canada). The allocation sequence was not available to any member of the research team until databases had been completed and locked. Participants and their parents, the anaesthesiologist, the endoscopist, and the procedure room and recovery room nurses were blinded to patient assignment. Group allocation was concealed in opaque, sequentially numbered envelopes. A single study investigator (C.P.) had access to the randomisation code to allow for preparation of the study drugs and in the case of an emergency event during the procedure.
Procedures
A standardised anaesthetic regimen was used in all subjects. Topical local anaesthetic (Ametop, amethocaine/tetracaine hydrochloride 4% gel; Smith and Nephew, Mississauga, ON, Canada) was applied to the dorsum of both hands at least 30 min before the procedure, unless declined by the subject or parent. An i.v. catheter was placed on the dorsum of the hand just before the procedure. The children were offered inhaled nitrous oxide 50e60% in oxygen during i.v. catheter placement, which was turned off immediately afterwards and the children were encouraged to 'washout' the nitrous oxide by taking two or three deep breaths of 100% oxygen before administering the first study drug. Vital signs monitors (electrocardiogram, pulse oximetry, and non-invasive blood pressure cuff) were applied before the induction of anaesthesia, along with nasal prongs to monitor exhaled carbon dioxide and administer oxygen if the pulse oximeter saturation decreased to 94%. Heart rate, ventilatory frequency, and oxyhaemoglobin saturation were monitored continuously during the procedure. An unblinded study investigator (C.P.), who did not participate in patient care during the sedation and endoscopy, prepared the study medications, and the doses were doublechecked by a non-investigator anaesthesiologist or anaesthesia assistant (S.J.) not participating in patient care. The ketamine dose was drawn into a 10-ml syringe with normal saline added to produce a final volume of 10 ml of solution. The appropriate dose of propofol (Propofol 1%; Fresenius Kabi Canada Ltd., Toronto, ON, Canada) for that patient, as determined by the study protocol (Table 1) , was drawn into either a 10 ml syringe (subjects aged 8 yr) or 20 ml syringe (subjects aged >8 yr) with 5% dextrose solution, as per product monograph, added to achieve a final volume of 10 and 20 ml, respectively, with a minimum concentration of 2 mg ml
À1
. The
Editor's key points
Ketamine is a commonly used sedative and analgesic adjunct during paediatric sedation and anaesthesia. The current study investigated the influence of three different doses of ketamine on propofol requirements for endoscopy. Ketamine reduced propofol requirements and was associated with better haemodynamic stability. administered at the discretion of the blinded anaesthesiologist to allow the patient to tolerate the remainder of the procedure. Patients were discharged home once awake and able to tolerate oral fluids, with vital signs in the normal range.
Study outcomes
ED 50
The determination of ED 50 of propofol was based on the empirical formula of Dixon and Massey (see Appendix 1 and online Supplementary data for detailed calculations). 15 The first patient in every ketamine group received a starting propofol dose that was estimated to be close to the anticipated ED 50 (Table 1) . If there was excessive movement, coughing, gagging, or airway obstruction that prevented complete insertion of the endoscope (i.e. failure or 'response'), as determined by the blinded anaesthesiologist (J.H. or C.M.), the dose for the next patient was increased by a fixed dose interval (Table 1) . If the patient tolerated complete insertion of the endoscope, the dose for the next patient was decreased by a fixed dose interval ( Table 1 ). The choices of the dose intervals were based on: 1) previously reported studies pertaining to sedation doses in paediatric patients 16e22 ; 2) our own clinical experience; and 3) our assumption that the dose response for the expected effect is steep with high slope value. The dose intervals were chosen based on the recommendation by Dixon and Massey that they lie between 0.5 and 2 times the anticipated standard deviation (SD). 15 23 Since the slope of the doseresponse relationship of propofol in the proposed study was anticipated to be steep, we used a dose interval that was equal to the assumed SD.
Vital signs monitoring
Heart rate was recorded at the following time points: at baseline, before study drug administration; at 1-min intervals during the procedure; on arrival to the recovery room; and at 15-min intervals during recovery until discharge. Mean arterial pressure was recorded at the following time points: at baseline before study drug administration; at 5-min intervals during the procedure; on arrival to the recovery room; and at 15-min intervals during the recovery phase until discharge.
Details of the procedure and recovery phase
The duration of the procedure (time of scope insertion to time of scope removal), ease of endoscope insertion, as rated by the blinded endoscopist using a 0e10 numeric rating scale (0¼very easy; 10¼very difficult), the cumulative dose of propofol required to complete the procedure, and the time to discharge readiness were recorded.
Adverse events
During the procedure, the following adverse events were recorded: duration of apnoea; occurrence of oxyhaemoglobin desaturation to <95%; need for airway management, such as jaw thrust, positive pressure ventilation, or insertion of an oral airway. During the recovery phase the occurrence of nausea/ vomiting, dizziness, visual disturbance, such as blurred or double-vision, nystagmus, hallucinations, emergence delirium using the Pediatric Anesthesia Emergence Delirium scale, 24 and the severity of pain assessed on a 0e10 numeric rating scale (0¼no pain, 10¼worst pain possible), were assessed and recorded.
Sample size calculations
We applied Dixon and Massey's approach for sample size calculation for the up-and-down method design to estimate the threshold for all-or-none responses. 15, 23 The anticipated mean and its SD and standard error were inferred from previous studies that investigated propofol and propofoleketamine combination in paediatric patients undergoing minor procedures. 16, 17 Also, our estimates were based on our clinical experience because of lack of relevant published data. Accordingly, we estimated that the mean propofol dose required to prevent movement or cough/laryngospasm during introduction of the endoscope when combined with 0.5 mg kg À1 ketamine in 50% of patients is 2.5 mg kg À1 with SD and standard error of the mean (SEM) of 1.25 and 0.5 mg kg À1 , respectively. Hence, the sample size needed to calculate the minimum effective dose of propofol that will produce a successful block of movement and prevent cough/laryngospasm during the introduction of the endoscope in 50% of individuals (ED 50 ) in the ketamine 0.5 mg kg À1 group will be equal to 2 (s/ sx), 2 where s and sx are the anticipated SD and SEM, respectively. Consequently, the formula generated the largest sample size, which we considered appropriate to apply to the other groups. We preferred equal sample sizes amongst the groups because our study was a randomised controlled study. Additionally, we tried to avoid a situation of unequal variances between the groups. Additionally, the sample size was increased by 10% to account for possible drop-outs and protocol violations. Hence, 14 patients were recruited for each ketamine group in the study.
Statistical analyses
Continuous data with parametric values was analysed using a one-way ANOVA for unpaired data with Bonferroni correction for multiple comparisons. Data with ordinal values was analysed using the KruskaleWallis test with Dunn's post-test for multiple comparisons. Categorical data was analysed using the c 2 test. Continuous data are reported as mean (SD), or median and interquartile range, as appropriate. Categorical data are reported as frequencies (%). A P-value <0.008 was considered significant according to the Bonferroni correction factor for multiple comparisons for the ED 50 calculations. For the adverse events results, P<0.05 was considered statistically significant.
Results
Eighty-seven patients were approached; 57 agreed to participate and 30 declined. One participant was excluded from analysis because of incorrect sequence of study drug administration (Fig. 1) , which left 56 participants who comprised the randomised controlled trial cohort.
There were no significant differences among subjects in the four study groups in terms of patients characteristics or procedural factors that could have introduced bias into the results ( Table 2 ). The Dixon up-and-down plots for each group are shown in Figure 2AeD . The ED 50 (95% CI) of propofol was significantly less in the ketamine 1 mg kg À1 group compared with the ketamine 0, 0.25, and 0.5 mg kg À1 groups [1.1 (0.5e1.8) mg kg À1 vs 6.1 (4.1e8.1), 4.5 (2.9e6), and 4.7 (3.1e6.2) mg kg À1 , respectively; P<0.008; Table 3 ]. There was no statistically significant difference between the ketamine 0, 0.25, and 0.5 mg kg À1 groups. The total dose of propofol [mean (SD)] required to complete the procedure was significantly greater in the Table 4 ). The mean arterial pressure was significantly lower in the ketamine 0 mg kg À1 group compared with the ketamine 1 mg kg À1 group during the procedure and on arrival to the recovery room (Table 5) . During the recovery phase, episodes of hypotension, defined a priori as >20% decrease in mean arterial pressure compared with baseline, occurred in >60% of patients in the ketamine 0 and 0.5 mg kg À1 groups, compared with 29% in the ketamine 1 mg kg À1 group (Table 5) . However, all episodes were self-limited and did not require intervention. The average duration of apnoea was shortest in the ketamine 1 mg kg À1 group, but the differences were not statistically significant (Table 6 ). More children in the ketamine 1 mg kg À1 groups experienced nausea and nystagmus/visual disturbance compared with the other three groups (Table 6 ).
Discussion
We have demonstrated that coadministration of ketamine 1 mg kg À1 leads to a significant reduction in the median dose (i.e.
ED 50 ) of propofol required to minimise or prevent movement, coughing, or gagging with endoscope insertion in children. To our knowledge, this is the first randomised controlled dosefinding study evaluating the combination of propofol and ketamine for deep sedation/anaesthesia for a brief, stimulating procedure in children. Several studies investigated certain aspects of the simultaneous administration of ketamine and propofol in children undergoing minor procedures. Geyik and colleagues 18 evaluated four different doses of ketamine in combination with propofol to produce deep sedation and immobility during MRI scans in children. In this study, each subject received a bolus of either propofol 1 mg kg À1, or ketamine 0.5, 1, or 1.5 mg kg
À1
, (14) 88 (18) 77 (8) 89 (15) 1 min 105 (19) 92 (35) 102 (23) 106 (18) 2 min 114 (16) 108 (13) 104 (16) 108 (17) 3 min 109 (14) 109 (20) 109 (19) (11) 72 (7) 90 (8) Hypotension (%) 1 (7) 2 (14) 1 (7) 0 (0) Postprocedure Heart rate (beats min À1 ) Arrival in recovery room
98 (10) 104 (9) 94 (12) 98 (21) 15 min 92 (14) 92 (10) 86 (12) 90 (21) 30 min 87 (9) 96 (13) 84 (12) 93 (15) 45 min 9 (17) 91 (21) 82 (13) 84 (10) (23) 9 (64)* Emergence delirium score (0e10 PAED scale) 0 (0e0) 0 (0e0) 0 (0e0) 0 (0e0) Pain score (0e10 NRS scale) 0 (0e0) 0 (0e0) 0 (0e0) 0 (0e2) Time to discharge readiness (min) 50 (7) 46 (4) 50 (9) 47 (5) followed by an infusion of propofol at 100 mg kg À1 min À1 , plus additional bolus doses of propofol as needed. There was a nonsignificant reduction in the total dose of propofol required as the dose of ketamine increased. However, the results of that study are not directly comparable to ours, as a propofol infusion, which was not adjusted according to depth of sedation, was used, and the duration and type of procedure (non-stimulating) were different. These factors may have mitigated the effects of increasing doses of ketamine on propofol requirements, and thus other outcomes. Other studies have compared a single-dose combination of ketamine and propofol to propofol-alone in terms of side effects and extent of sedation. 17,19À22,25 Ketamine doses ranged from 0.5 to 0.8 mg kg
, and were administered as a single bolus or infusion, either separately or mixed with propofol in the same syringe. The reduction in propofol requirements with ketamine varied widely (20e50%) across studies. This may be a result of the different types and duration of procedures performed, the use of propofol infusions in conjunction with propofol boluses as needed, the use of adjunct drugs, such as an opioid or benzodiazepine, and the use of the 'same-syringe' technique, whereby propofol and ketamine are mixed in a fixed ratio, such as 2:1 or 3:1, in the same syringe. Since the optimal dose ratio of propofol to ketamine is unknown, 13, 26 this technique is particularly problematic in children because of the potential for over-administration of propofol or ketamine, depending on the ratio used. Thus, the above studies were designed to specifically assess the effective doses of propofol or ketamine required for the procedures. Our study adds new knowledge by identifying an optimal relationship between ketamine and propofol for deep sedation/general anaesthesia for a stimulating procedure in children. Our findings show that the greatest reduction in the ED 50 of propofol, a decrease of 77%, occurred with an increase in ketamine dose from 0.5 to 1 mg kg
, compared with a decrease of only 23% with ketamine 0.5 mg kg À1 compared with control. Additionally, the total dose of propofol required to complete the procedure was reduced by 35%, to 3.4 (1.9) mg kg
. Our findings are corroborated by a simulation study that used paediatric and adult pharmacokinetice pharmacodynamic models to predict the optimal dose ratios of propofol to ketamine to achieve deep sedation with the shortest recovery times. 26 The authors concluded that a propofol to ketamine ratio of 3:1 would be most suitable to provide procedural sedation in a child for up to 10 min. The slightly higher dose of propofol in our study may be attributable to the target level of sedation, which was general anaesthesia, compared with deep sedation in the simulation study. Although the incidence of hypotension, defined as a decrease in the mean arterial pressure >20% from baseline, was not different between the groups in our study, the relative decreases in mean arterial pressure, particularly during the recovery phase, were greater in the ketamine 0, 0.25, and 0.5 mg kg À1 groups, which received significantly higher doses of propofol compared with the ketamine 1 mg kg À1 group. This may also explain the trend to a longer duration of apnoea in the former groups. Our findings are consistent with previously published paediatric studies comparing the combination of ketamine and propofol with propofol alone. Most studies reported more stable haemodynamic parameters and a lower incidence of respiratory adverse events 17, 19, 20, 27, 28 with the addition of ketamine, although a minority showed no significant difference. 21, 22, 25 Two recent meta-analyses of procedural sedation in children and adults in the emergency department, 4,13 which included the aforementioned studies, reported that the risk ratios for hypotension, bradycardia, and respiratory adverse events significantly favoured the combination of ketamine and propofol compared with propofol alone. Interestingly, we found a significant increase in the incidence of nausea/vomiting and nystagmus/visual disturbances, known adverse effects of ketamine, in the ketamine 1 mg kg À1 group, whereas previous paediatric studies reported no significant difference. Some study limitations merit emphasis. We determined and reported the median effective dose (ED 50 ) and did not calculate ED 95 values. To do so using up-and-down methodology requires extrapolation and boot-strapping of data. This can result in values with relatively large 95% confidence intervals, which need to be interpreted with extreme caution. Based on our previous experience, 29 we preferred not to use methods that are aiming to more directly determine the ED 95 dose. 30 We were concerned about the practical risks of significant cardiovascular and respiratory adverse events, such as hypotension and prolonged apnoea and desaturation, which may occur with large (i.e. ED 95 ) doses of propofol, especially in the ketamine 0 mg kg À1 group. Such large doses can be unsafe to study participants (and would probably not receive ethics approval) and may result in the occurrence of unacceptable adverse events. Another limitation is the lack of a ketamine dose between 0.5 and 1 mg kg À1 . Since the optimal dose combination of ketamine and propofol is unknown, the choice of ketamine doses was based on the investigators' clinical experience, which assumed a highly synergistic Hill-type dose-response relationship between ketamine and propofol at lower (<0.5 mg kg À1 ) doses of ketamine.
In summary, this report suggests that increasing the dose of ketamine above 0.5 up to 1 mg kg À1 significantly reduces the dose of propofol required to provide deep sedation and general anaesthesia for procedural sedation in children and may reduce the incidence and severity of propofol-related changes in haemodynamic parameters. The authors recommend using a dose combination of propofol and ketamine in approximately a 3:1 ratio for deep sedation/general anaesthesia for painful or stimulating procedures. However, the specific dose requirements may vary depending on the type, duration, and depth of sedation required for the specific procedure, and dosages should be titrated accordingly. Although higher ketamine doses may reduce the dose of propofol and related side effects to a more significant degree, they may significantly increase the incidence of ketaminerelated adverse effects. 
